Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer
Phase 2 Unknown
138 enrolled
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
Phase 1/2 Unknown
30 enrolled
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer
Phase 1/2 Unknown
50 enrolled
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2 Unknown
30 enrolled
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer
Phase 2 Unknown
30 enrolled
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
Phase 2 Unknown
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
Phase 2 Unknown
100 enrolled
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Phase 2 Unknown
17 enrolled
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Phase 3 Unknown
Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
Phase 3 Unknown
1,000 enrolled
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
Phase 2 Unknown
Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Phase 3 Unknown
300 enrolled
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
Phase 1/2 Unknown
46 enrolled
Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer
Phase 2 Unknown
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
Phase 2 Unknown
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer
Phase 1 Unknown
Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Phase 1 Unknown
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase 1 Unknown
Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer
Phase 3 Unknown
250 enrolled
Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer
Phase 3 Unknown
430 enrolled
Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Unknown
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Unknown
88 enrolled
Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
Phase 2 Unknown
50 enrolled
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase 2 Unknown
160 enrolled
Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
Phase 2 Unknown
60 enrolled
Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 2 Unknown
150 enrolled
Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Unknown
26 enrolled
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
Phase 3 Unknown
140 enrolled
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Phase 1 Unknown
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
Phase 3 Unknown
800 enrolled
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
Phase 3 Unknown
2,500 enrolled
Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
Phase 1 Unknown
Combination Chemotherapy in Treating Patients With Solid Tumors
Phase 1 Unknown
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
Phase 2 Unknown
100 enrolled
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Phase 2 Unknown
250 enrolled
Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus
Phase 1/2 Unknown
Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer
Phase 3 Unknown
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
Phase 2 Unknown
100 enrolled
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
Phase 2 Unknown
60 enrolled
Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
Phase 2 Unknown
Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 2 Unknown